Roth Capital Initiates Solazyme With Buy

Roth Capital initiated coverage on shares of Solazyme SZYM with a Buy rating. The target price for Solazyme is set to $6. Solazyme shares have dropped 11.99% over the past 52 weeks, while the S&P 500 index has gained 15.82% in the same period. Solazyme's shares rose 2.04% to close at $7.49 yesterday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: InitiationAnalyst RatingsRoth Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!